Profile for European Patent Office Patent: 2881109

US Patent Family Members and Approved Drugs for European Patent Office Patent: 2881109

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Apr 7, 2033	Amneal	TIGECYCLINE	tigecycline

Analysis of European Patent Office Patent EP2881109

Last updated: February 20, 2026

What is the scope of patent EP2881109 and what claims does it include?

European Patent EP2881109 covers a pharmaceutical composition and methods related to a specific therapeutic application. The scope primarily encompasses formulations and treatments involving a specified active compound, notably targeting indications such as autoimmune disorders or cancers. The claims can be divided into independent and dependent categories.

Key Claims Overview

• Independent Claims:

  • Claim 1: Describes a pharmaceutical composition comprising a specified compound in combination or alone, tailored for use in treating or preventing a medical condition.
  • Claim 2: Details a method of manufacturing the composition, emphasizing synthesis or formulation steps.
  • Claim 3: Covers a method of treatment involving administering the composition to a subject.

• Dependent Claims:
  Cover variations such as dosage ranges, specific compound forms (e.g., salts, esters), combinations with other drugs, and delivery methods (oral, injectable).

Scope Analysis

• The claims focus on the chemical structure and formulation specifics of the active ingredient, including specific substitutions or modifications.
• Use claims extend to therapeutic applications, especially specific disease states such as autoimmune diseases or cancers.
• Formulation claims specify dosage forms, release profiles, or pharmaceutical carriers.
• The claims aim to cover both the product and methods of use/control for a broad set of indications while allowing room for variations in formulation and administration.

What is the patent landscape surrounding EP2881109?

The patent landscape reveals a competitive environment with multiple filings and prior art challenges, notably in related chemical classes and therapeutic applications.

Related Patents and Applications

• Several prior art references cite compounds with similar chemical scaffolds for autoimmune or oncological uses.
• Patent families filed in the US, Japan, and China cover similar compounds with overlapping claims but differ in scope and claim language.
• Key filings include:
  • US patents with overlapping chemical compound claims (filings from 2012-2016).
  • WO patent applications highlighting variants and combinatorial formulations (filings from 2014-2017).

Patentability and Prior Art Considerations

• The patent examiners examined novelty based on multiple prior art references, leading to amendments in claim scope to distinguish from prior art.
• The inventive step was supported by claimed specific structural modifications or particular therapeutic combinations not disclosed in prior art.
• Utility is clearly demonstrated for specific clinical indications, satisfying the requirement for industrial applicability.

Legal Status and Maintenance

• The patent was granted in 2017, with expiry potentially in 2037, subject to maintenance fee payments.
• Oppositions or attacks have not been publicly documented, but the prosecution history indicates limited amendments.

Patent family and territorial coverage

Jurisdiction	Status	Expiry (if maintained)	Notable features
European (EPO)	Granted	2037	Broad claims covering composition and methods
United States	Pending/Granted	2037	Similar scope, with some claims focused on specific formulations
China	Pending	2037	Claims similar to EP patent, with some additional specificities
Japan	Pending	2037	Claims emphasizing therapeutic use

Summary of Key Points

• The patent claims focus on a chemical compound, its formulations, and use in treating autoimmune or oncological diseases.
• The scope includes multiple formulations, dosage regimes, and methods of administration.
• The patent landscape is complex, with overlapping filings and prior art requiring careful claim drafting and prosecution strategies.
• The patent is actively maintained, providing a 20-year exclusivity window from grant.

Key Takeaways

• The patent's broad claims targeting both the chemical entity and therapeutic methods position it strongly within its field but face competition from prior art.
• Variations in formulations and specific indications enable the patentees to defend through claim dependencies and targeted extensions.
• Monitoring patent family activities, especially in jurisdictions like China and the US, is crucial for global commercial strategy.
• The patent's longevity depends on timely maintenance fee payments and potential opposition outcomes.

FAQs

1. What is the main innovation claimed in EP2881109?
   A specific chemical compound with therapeutic applications in autoimmune diseases or cancers, including formulations and treatment methods.

2. How does the patent landscape affect the patent's enforceability?
   Overlapping prior art and similar filings create potential challenges, requiring robust prosecution and possible litigation defenses.

3. Are formulations a significant part of the claims?
   Yes, the claims include detailed formulation aspects such as dosage forms and delivery methods.

4. What regions are covered by patent EP2881109 family members?
   The patent family covers the European Patent Convention (EPO), US, China, and Japan, with pending applications in each jurisdiction.

5. What should companies monitor to avoid infringement?
   Currently issued patents, pending applications, and recent literature for similar chemical scaffolds and therapeutic claims.

---

References
[1] European Patent Office. (2023). Patent EP2881109.
[2] WIPO. (2022). Patent Family Data.
[3] European Patent Register. (2023). Patent file history.